Drug Profile
Research programme: CNS disorders therapeutics - Chronos Therapeutics
Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Shire
- Developer Chronos Therapeutics
- Class
- Mechanism of Action Central nervous system modulators; Orexin receptor type 1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Fatigue; Impulse control disorders; Post-traumatic stress disorders
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for preclinical development in Fatigue in United Kingdom
- 28 Aug 2020 No recent reports of development identified for preclinical development in Impulse-control-disorders in United Kingdom
- 28 Aug 2020 No recent reports of development identified for preclinical development in Post-traumatic-stress-disorders in United Kingdom